📰 Mark Bleackley News
Page 2 - Mark Bleackley News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Mark Bleackley. Real-time updates on events, politics, business and more.
July 13, 2023
Incannex Healthcare Limited (NASDAQ: IXHL) (ASX:IHL) has received approval from Bellberry Human Research Ethics Committee (‘HREC’) for the lead site, Emeritus Research, Camberwell, Victoria, for its phase 2 clinical trial.
July 6, 2023
Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) has garnered ethics approval to conduct a clinical trial for its proprietary drug, IHL-42X, aimed at treating...
July 6, 2023
Date: July 06, 2023 Public Announcement Incannex Receives Ethics Approval for...
July 6, 2023
Incannex Healthcare Limited (NASDAQ: IXHL) (ASX:IHL) has received approval from Bellberry Human Research Ethics Committee to commence a bioavailability/bioequivalence (‘BA/BE’) clinical trial on IHL-42X, the company’s proprietary drug prod
July 6, 2023
Incannex received ethics approval to begin a bioavailability/bioequivalence clinical trial on IHL-42X, a drug candidate to treat OSA.
May 2, 2023
Final results are in for a Phase 1 clinical trial to assess pharmacokinetics and the safety of Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL)’s...
May 2, 2023
MELBOURNE, Australia, May 02, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’) a...
March 3, 2023
Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) has engaged Catalent Pharma Solutions for the development and cGMP manufacture of its psilocybin drug...
March 3, 2023
Highlights: Incannex has engaged Catalent for the development and cGMP manufacture of Incannex’s own psilocybin drug product.The psilocybin is designed...
February 28, 2023
Highlights: Incannex has commenced a Phase 2, Blinded, Placebo Controlled Clinical Trial to Determine the Safety and Effect on Pain and Function of...